Beta-amyloid short- and long-term synaptic entanglement.

Area of Science:

• Neuroscience
• Biochemistry
• Molecular Biology

Background:

• Beta-amyloid (Aβ) is central to Alzheimer's disease (AD) pathology, driving neurodegeneration.
• The amyloid cascade hypothesis guided AD therapeutics, but clinical trials targeting Aβ have largely failed.
• Aβ is endogenously produced by brain cells, suggesting physiological roles.

Purpose of the Study:

• To review the emerging evidence for Aβ's physiological role in modulating synaptic activity.
• To examine the interplay between Aβ and various neurotransmitter systems.
• To understand Aβ's mechanisms of action at the synaptic level.

Main Methods:

• Literature review of studies on Aβ's physiological effects.
• Analysis of Aβ's interaction with neurotransmitter systems (cholinergic, glutamatergic, GABAergic, etc.).
• Investigation of Aβ's molecular interactions with synaptic proteins.

Main Results:

• Aβ exhibits a dual role: neuromodulatory/neuroprotective at physiological concentrations and neurotoxic at higher levels.
• Physiological Aβ concentrations modulate synaptic activity and interact with key neurotransmitter systems.
• Aβ interacts with synaptic proteins involved in neurotransmitter release machinery.

Conclusions:

• Aβ's concentration-dependent dual role challenges its sole pathogenic view in AD.
• Understanding Aβ's physiological synaptic functions is crucial for novel therapeutic strategies.
• Altered neurotransmitter activity may serve as early biomarkers for AD development.